#GateIdleEarnAutoYieldUpTo3% #$MU Citi Cuts Micron Price Target, but the Rationale Doesn’t Hold

#$MU Citi Cuts Micron Price Target, but the Rationale Doesn’t Hold
On August 7, Citi cut Micron’s price target from $1,400 to $1,150, while maintaining a Buy rating. Ten days later, UBS published a report written after accompanying Micron’s management on a roadshow, with a $1,625 price target and the same Buy rating. The two targets differ by $475. But when you compare the earnings forecasts, they are almost identical. UBS estimates Micron will earn $148 per share in calendar 2028, while Citi estimates $148.60, a difference of less than 1%. The two firms do not disagree on how much Micron can earn. The disagreement is over how many times those profits are worth.

01 What Exactly Did Citi Cut?
Citi published this report on August 7. The analysts were Atif Malik, James Bowlin, and Kelsey Chia, and the report was 14 pages long. Its pricing benchmark was the August 6 closing price of $881.47. The new price target of $1,150 corresponds to 8 times expected calendar 2027 earnings per share, versus 10 times previously. The earnings forecast section barely changed: fiscal 2027 was lowered by 1% and fiscal 2028 by 2%. In other words, Citi’s view of how much Micron can earn was basically unchanged; what changed was how much it believes the market is willing to pay for those profits. The price target was cut by 17.9%, of which only 1% to 2% came from earnings adjustments. The rest came entirely from compressing the valuation multiple. Supporting that decision was a DRAM price trajectory.
Citi expects the rate of increase to narrow each quarter: still more than 20% in the August quarter, below 10% in the November quarter, just 2% next February, zero in May, and down 5% in the second half of 2027.
NAND is expected to follow a similar path. The corresponding gross margin would decline from around 85% to around 75%. Section 4.4 of the report also contains a detail that was left out of the summary and mentioned in none of the articles that relayed it: around 40% of Micron’s DRAM output is covered by long-term contracts, the lowest among the four major memory manufacturers. The remaining roughly 60% is exposed to spot-market pricing, giving Micron greater exposure than Samsung and SK hynix.

02 UBS Heard a Different Story from Management
On August 17, UBS published “Walking Alongside Management.” The report was written after accompanying Micron’s management on an investor roadshow. It assigned a Buy rating and a $1,625 price target, 41% above Citi’s. The disagreement between the two firms centers on three areas.
First, their views on the price trend are completely opposite. Citi believes DRAM price increases will diminish each quarter, reach zero by the middle of next year, and turn negative in the second half. UBS recorded management’s exact words as follows: supply and demand in calendar 2027 will be tighter than in 2026. Micron currently can meet less than half of data-center customer demand, while average HBM selling prices are still rising. UBS also listed the capacity timeline: most of the new capacity in 2027 will come from expansions at two older fabs, and the volume will be limited. Truly large-scale production will not begin until 2028. Supply pressure has been pushed back by a year. Citi says “the peak is near,” while management says “we haven’t reached the peak yet.” Within ten days, the pricing line had been drawn in the opposite direction.
Second, their descriptions of long-term contract coverage differ. Citi says around 40% of Micron’s output is covered by long-term contracts, the lowest among the four. UBS was the first to break down the structure of Micron’s strategic customer agreements: the goal is to bring more than 50% of revenue under contractual protection, with around 10% covered by “take-or-pay” agreements (customers can decline delivery but still have to pay; prices are not fixed), and another roughly 40% carrying fixed prices or price ranges. Citi uses an output-based measure, while UBS uses a revenue-based measure, so the two figures cannot be compared directly. But the direction of their statements is opposite: Citi says “the least is locked in,” while UBS says “more than 50% of revenue has three layers of protection.”
Third, their valuation benchmarks differ by a full year. Citi uses 8 times calendar 2027 earnings. UBS uses 11 times calendar 2028 earnings of $148 per share. Citi’s own forecast for Micron’s fiscal 2028 earnings is $148.60 per share. Multiplying Citi’s earnings forecast by UBS’s multiple produces $1,635, just 0.6% above UBS’s $1,625.
The two firms differ by $475, their earnings forecasts are almost identical, and the entire disagreement lies in “which year to look at” and “what multiple to assign.”

03 Both Firms Have Conflicts of Interest
Citi itself discloses a medium-high conflict level, including investment banking compensation and significant financial interests.
UBS is more noteworthy: it holds a short position of more than 0.5% in Micron and is also a market maker in Micron stock, yet it assigned a Buy rating and the highest price target on Wall Street. One firm has investment banking business with the company but cut its price target. The other is short the stock but set the highest price target. Neither side has clean interests.

04 Citi’s Cut This Time Does Not Hold Up
Citi changed its earnings forecasts by only 1% to 2%, yet cut its price target by 17.9%. What was cut was not Micron’s earnings power, but the valuation multiple Citi believes the market should assign. That is a subjective judgment, not a business discovery.
More importantly, the pricing premise supporting that judgment—that DRAM price increases would diminish each quarter and reach zero by the middle of next year—was directly denied by Micron’s management just ten days after the report was released. Management said 2027 would be tighter than 2026, new capacity would not arrive until 2028, and the company currently cannot even meet half of data-center demand. Citi also has an internal contradiction. It maintains a Buy rating while keeping its earnings forecasts 13% to 15% below market consensus. Its reason for being bullish on Micron is that the stock is cheap, but its own model does not support the claim that “the company can earn more.” $1,150 looks more like a conservative floor. But UBS’s $1,625 cannot be accepted uncritically either. That target was set on May 26 and has not been updated for three months. A price target left unchanged for three months is closer to a statement of conviction. Moreover, the institution that issued it is itself holding a short position in Micron.
SUMMARY The only defensible conclusion is this:
Citi’s cut this time was driven by the valuation multiple, not the fundamentals. Reducing a position based on it means following Citi’s valuation preference, not following changes in Micron’s operations. As for whether Micron should continue to be held, all three reports sidestepped the same key question: does HBM production count toward that 40% long-term contract coverage? This gap determines how much pricing exposure Micron’s conventional DRAM actually has. None of the three reports provides an answer.

What to watch next
① If Micron discloses long-term contract coverage clearly above 40% in its next earnings report, the claim that it is “the least locked in among the four” will no longer hold.
② If DRAM prices really follow the line Citi drew—with the increase falling below 10% in the November quarter and to just 2% next February—then management was wrong and Citi was right.
③ If UBS’s next update still leaves the target at $1,625, not changing it for three months is conviction; not changing it for six months means it is no longer being tracked. $MU ‌